Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00066599 · ClinicalTrials.gov registry record · Phase 2
Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00066599: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00066599 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00066599, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who have neutropenia after receiving chemotherapy for leukemia, lymphoma, or aplastic anemia or in preparation for bone marrow or stem cell transplantation.
Interventions
- DRUG voriconazole
Trial Details
| Field | Value |
|---|---|
| Start Date | 2003-06 |
| Est. Completion | 2004-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00066599
The ClinicalTrials.gov registry entry for NCT00066599 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which voriconazole is the first listed.
NCT00066599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00066599 about?
NCT00066599 is a clinical study titled "Voriconazole in Preventing Fungal Infections in Children With Neutropenia After Chemotherapy". RATIONALE: Voriconazole may be effective in preventing systemic fungal infections following chemotherapy. PURPOSE: Phase II trial to study the effectiveness of voriconazole in preventing systemic fungal infections in children who have neutropenia after receiving chemotherapy for leukemia, lymphoma,...
What is the current status of trial NCT00066599?
This trial is currently completed. It is a Phase 2 study. The study started on 2003-06. Estimated completion is 2004-06.
What interventions are being tested in trial NCT00066599?
The interventions under investigation include: voriconazole (DRUG).
Who is sponsoring clinical trial NCT00066599?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.